Speaker Interview with Elodie Baumfeld Andre 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress

Speaker Interview with  Elodie Baumfeld Andre 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress

Boston, September 9, 2019 – MarketsandMarkets recently interviewed Elodie Baumfeld Andre, Senior Director, Epidemiology Strategy Lead, Worldwide Medical & Safety, Pfizer regarding 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress taking place on October 24 – 25, 2019 at DoubleTree by Hilton Boston-Downtown . Elodie Baumfeld Andre is the Epidemiology Strategy Lead within the Worldwide Medical & Safety group at Pfizer. In this role, Elodie’s focus is on generating Real World Evidence (RWE) to support regulatory decision-making and driving continued innovation by implementing novel clinical designs and developing operating models. She is…

Read More

Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

London, September 3, 2019 – MarketsandMarkets recently interviewed Dr. Susan Astley, Division of Informatics, Imaging & Data Sciences, University of Manchester regarding MarketsandMarkets Biomarker and Companion Diagnostics Conference taking place on 3rd – 4th October 2019 at Radisson Blu Edwardian, Grafton, London, UK Q. What are the recent advances in Biomarker research/commercialization and current challenges that need immediate attention? A. The era of personalised medicine is with us. Biomarkers are crucial to identify those at risk of particular diseases, and those who would benefit from different preventative or therapeutic interventions….

Read More

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City.  Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. The major advance has been to crack the code of immunosuppression induced by cancer, especially via checkpoint inhibitors such as antibodies to CTLA4 and PD-1/PD-L1.  This has made many tumors amenable to immunotherapy.  However, the generalized nature of…

Read More

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and located in New-York. There, he leads the three early pipeline programs, including a novel irreversible BTK inhibitor, and anti-PD-L1 monoclonal antibody and a bispecific antibody directed against CD19 and CD47. All three assets have entered…

Read More

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Frank Borriello, CEO, Alloplex Biotherapeutics, regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. While there have been many advances in the field of cellular therapy in oncology, the common element limiting their adoption will be reproducibility of manufacturing, whether autologous or allogeneic, as well as generalizability across multiple tumor types, whether…

Read More

Speaker Interview With Alfred Budillon FOR 4th Annual MarketsandMarkets Epigenetics Congress

Speaker Interview With Alfred Budillon FOR 4th Annual MarketsandMarkets Epigenetics Congress

London, UK July 30, 2019 – MarketsandMarkets recently interviewed Alfred Budillon, Chief Experimental Pharmacology Unit Department, Istituto Nazionale Tumori, Italy regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained the PhD in Oncology from University G. D’Annunzio of Chieti, Italy, and a master’s degree in health economy, Management and Bioethics. Dr. Budillon is currently the chief of Experimental Pharmacology, National Cancer Institute…

Read More

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets Epigenetics Congress

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets  Epigenetics Congress

London, UK July 29, 2019 – MarketsandMarkets recently interviewed Gavin Reynolds, Professor Emeritus, Queen’s University Belfast, UK regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Gavin Reynolds is Honorary Professor at Sheffield Hallam University and Professor Emeritus, previously Chair of Neuroscience, at Queen’s University Belfast. His main research interests lie in two directions: the neurotransmitter pathology of schizophrenia, and the mechanisms underlying the beneficial and adverse effects of antipsychotics and other psychoactive drugs, with a recent focus on pharmacogenetic and…

Read More

Speaker Interview with Lorenzo Pasquali for 4th Annual MarketsandMarkets Epigenetics Congress

Speaker Interview with Lorenzo Pasquali for 4th Annual MarketsandMarkets Epigenetics Congress

London, UK July 23, 2019 – MarketsandMarkets recently interviewed Lorenzo Pasquali, Group Leader, Endocrine Regulatory Genomics Laboratory IGTP, Spain regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Lorenzo Pasquali is Group Leader of the Endocrine Regulatory Genomics laboratory at IGTP, Barcelona, Spain . His studies helped to map the epigenetic landscape of the insulin producing pancreatic islet cells resulting in milestone publications that opened the path to understand genomic regulation of the islets of Langerhans and shed…

Read More

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Read More

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

Read More